Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Haemonetics (HAE) over the last 17 years, with Q4 2025 value amounting to $10.1 million.

  • Haemonetics' Gains from Investment Securities rose 621562.5% to $10.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $38.6 million, marking a year-over-year increase of 9326.8%. This contributed to the annual value of $17.1 million for FY2025, which is 1023.73% up from last year.
  • Haemonetics' Gains from Investment Securities amounted to $10.1 million in Q4 2025, which was up 621562.5% from $7.9 million recorded in Q3 2025.
  • Haemonetics' 5-year Gains from Investment Securities high stood at $19.8 million for Q4 2022, and its period low was -$429000.0 during Q4 2021.
  • For the 5-year period, Haemonetics' Gains from Investment Securities averaged around $6.2 million, with its median value being $4.3 million (2023).
  • In the last 5 years, Haemonetics' Gains from Investment Securities tumbled by 9488.65% in 2024 and then soared by 641487.6% in 2025.
  • Haemonetics' Gains from Investment Securities (Quarter) stood at -$429000.0 in 2021, then skyrocketed by 4717.72% to $19.8 million in 2022, then tumbled by 84.2% to $3.1 million in 2023, then tumbled by 94.89% to $160000.0 in 2024, then soared by 6215.62% to $10.1 million in 2025.
  • Its last three reported values are $10.1 million in Q4 2025, $7.9 million for Q3 2025, and $18.1 million during Q2 2025.